These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 26714320

  • 1. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP.
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [Abstract] [Full Text] [Related]

  • 2. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T, Sun F, Li Y, Chen J, Chen X, Li R, Ge S, Zhao Y, Zhang W.
    BMC Infect Dis; 2021 Feb 17; 21(1):183. PubMed ID: 33596848
    [Abstract] [Full Text] [Related]

  • 3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee.
    J Assoc Physicians India; 2006 Mar 17; 54():219-34. PubMed ID: 16800350
    [Abstract] [Full Text] [Related]

  • 4. Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.
    Dudnyk A, Hempel M, Lytvyniuk O, Liudkevych H, Matsera V, Nikitchenko T, Blyzniuk S, Molina-Moya B, Preyer R, Domínguez J.
    Ther Adv Respir Dis; 2024 Mar 17; 18():17534666241249841. PubMed ID: 38817020
    [Abstract] [Full Text] [Related]

  • 5. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
    Bastos ML, Cosme LB, Fregona G, do Prado TN, Bertolde AI, Zandonade E, Sanchez MN, Dalcolmo MP, Kritski A, Trajman A, Maciel ELN.
    BMC Infect Dis; 2017 Nov 14; 17(1):718. PubMed ID: 29137626
    [Abstract] [Full Text] [Related]

  • 6. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ.
    Trials; 2019 Jan 16; 20(1):57. PubMed ID: 30651149
    [Abstract] [Full Text] [Related]

  • 7. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.
    Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, Steingart KR, Dheda K.
    Cochrane Database Syst Rev; 2014 Oct 29; (10):CD010705. PubMed ID: 25353401
    [Abstract] [Full Text] [Related]

  • 8. Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing.
    Chen X, He G, Lin S, Wang S, Sun F, Chen J, Zhang W.
    mSphere; 2020 Dec 23; 5(6):. PubMed ID: 33361124
    [Abstract] [Full Text] [Related]

  • 9. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM, Kundnani V, Agashe V, Nene A, Nene A.
    Spine (Phila Pa 1976); 2009 Oct 15; 34(22):E806-10. PubMed ID: 19829244
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P, Chitsaz E, Tabatabaei V, Baghaei P, Shamaei M, Farnia P, Marjani M, Kazempour M, Mansouri D, Masjedi MR, Velayati AA.
    Am J Ther; 2011 Sep 15; 18(5):343-9. PubMed ID: 20535008
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
    Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, Groenheit R, Hammar U, Giske CG, Schön T, Bruchfeld J.
    Clin Infect Dis; 2019 Sep 27; 69(8):1394-1402. PubMed ID: 30561569
    [Abstract] [Full Text] [Related]

  • 16. Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon.
    Noeske J, Voelz N, Fon E, Abena Foe JL.
    BMC Res Notes; 2012 Mar 21; 5():160. PubMed ID: 22436423
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH, Kang BH, Lee T, Lee HK, Jang HJ, Cho YJ, Jeon D.
    J Korean Med Sci; 2017 Apr 21; 32(4):636-641. PubMed ID: 28244290
    [Abstract] [Full Text] [Related]

  • 19. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia.
    Putri FA, Burhan E, Nawas A, Soepandi PZ, Sutoyo DK, Agustin H, Isbaniah F, Dowdy DW.
    Int J Tuberc Lung Dis; 2014 May 21; 18(5):564-70. PubMed ID: 24903794
    [Abstract] [Full Text] [Related]

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.